Talis Biomedical Corp

NASDAQ: TLIS    
Share price (5/17/24): $8.98    
Market cap (5/17/24): $16.4 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 2 pages April 10, 2024 Retention Agreement #2 Rebecca Markovich [Address Redacted] [...]@Gmail.com
12/34/56
EX-10.1
from 8-K 3 pages Amendment to Waiver of Registration Rights [Signature Page Follows]
12/34/56
EX-10.24
from 10-K 3 pages Waiver of Registration Rights
12/34/56
EX-10.7
from 10-Q 2 pages November 13, 2023 Rebeccamarkovich 3007 N Honore St Chicago, Il 60657 [...]@Gmail.com
12/34/56
EX-10.1
from 8-K 5 pages Material contract
12/34/56
EX-10
from 10-K 15 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Attachment 1 to the Termination Agreement License Agreement
12/34/56
EX-10
from 10-K 5 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Terminaton and Release Agreement
12/34/56
EX-10
from 10-K 12 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Consent to Sublease
12/34/56
EX-10
from 10-K 27 pages This Sublease (“Sublease”), Dated March 16, 2023 ( “Execution Date”), Is Entered Into by and Between Kriya Therapeutics, Inc., a Delaware Corporation (“Sublandlord”), and Talis Biomedical Corporation, a Delaware Corporation (“Subtenant”). 1. Basic Sublease Provisions
12/34/56
EX-10
from 10-K 11 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Lease Termination Agreement
12/34/56
EX-10.3
from 10-Q 4 pages Talis Biomedical Corporation Non-Employee Director Compensation Policy Effective Date: February 11, 2021 Amended and Restated: May 25, 2022
12/34/56
EX-10.2
from 10-Q 13 pages Talis Biomedical Corporation 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: February 5, 2021 Approved by the Stockholders: February 5, 2021 Ipo Date: February 11, 2021 Amendment Adopted by the Board of Directors: March 7, 2022 Amendment Adopted by the Stockholders: June 10, 2022
12/34/56
EX-10.1
from 10-Q 51 pages Talis Biomedical Corporation 2021 Equity Incentive Plan Adopted by the Board of Directors: February 5, 2021 Approved by the Stockholders: February 5, 2021 Ipo Date: February 11, 2021 Amendment Adopted by the Board of Directors: March 7, 2022 Amendment Adopted by the Stockholders: June 10, 2022
12/34/56
EX-10.17
from 10-K 12 pages Purchase Agreement
12/34/56
EX-10.8
from 10-K 20 pages Talis Biomedical Corporation Severance and Change in Control Plan
12/34/56
EX-10.7
from 10-K 3 pages Talis Biomedical Corporation Non-Employee Director Compensation Policy Effective Date: February 11, 2021 Amended and Restated: December 17, 2021
12/34/56
EX-10.1
from 8-K 4 pages Material contract
12/34/56
EX-10.2
from 10-Q 6 pages Talis Biomedical Corporation Rsu Award Grant Notice
12/34/56
EX-10.1
from 10-Q 13 pages August 28, 2021 Brian Coe Re:separation and Consulting Agreement 1. Resignation Dates
12/34/56
EX-10.4
from 8-K 7 pages Talis Biomedical Corporation Rsu Award Grant Notice
12/34/56